8-Year check: does the hydrus implant keep glaucoma in check?
NCT ID NCT07460791
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 200 glaucoma patients who received a tiny eye implant called Hydrus along with cataract surgery. Researchers want to see if the implant still helps control eye pressure after 8 to 14 years. The goal is to understand how well the implant works over the long term and whether it reduces the need for eye drops.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hydrus implant (a tiny stent placed in the eye to help drain fluid) plus cataract surgery (phacoemulsification)
What this could lead to
If successful, this could show that the Hydrus implant provides long-lasting eye pressure control for glaucoma patients, reducing the need for daily eye drops.
What could go wrong
This is an observational follow-up study, not a new treatment test. It only looks back at past results, so it cannot prove the implant works better than other options. Some patients may still need additional treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Opthalmology
RECRUITINGMainz, Rhineland-Palatinate, 55131, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••